Xanax for anxiety will be overshadowed by the next class of drugs in the psychedelic market. I look for AZN to buyout MNMD and or ATAI in the very near future. Both company hot on the tails of these big players with multiple phase 3 trials underway with LSD and DMT for GAD, MDD and TRD. LSD already has FDA breakthrough status designation. Big things are coming.
Market Data 
Markets 
AI
